Jared Whitlock

Reporter

Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Halozyme Nets $30 Million Upfront in Argenx Licensing Deal

Halozyme has licensed its drug delivery technology to yet another company.

Nanomedical Diagnostics Changes Company Name

San Diego-based Nanomedical Diagnostics is now known as Cardea.

Relatively Cheap Rent in County a Sweetner for Biotechs

San Diego lab rents in the prior four years were consistently lower than the country’s two larger life sciences markets, San Francisco and Boston.

Tease photo

PE Firm Buys Stake In S.D.-Based BioDuro

Private equity firm Advent International bought a majority stake in San Diego-headquartered BioDuro for an undisclosed amount, according to a recent announcement.

Tease photo

Gossamer Bio Is Back on Track For a Traditional IPO

With the government shutdown over, Gossamer Bio will take a traditional path to an initial public offering, abandoning a plan to sidestep the U.S. Securities and Exchange Commission.

Tease photo

Gossamer Bio Back to a Traditional IPO Path

With the government shutdown over, Gossamer Bio is expected to take a traditional path to an initial public offering, abandoning a plan to sidestep the U.S. Securities and Exchange Commission.

Tease photo

Neurocrine Bags Gene Therapies for $165 Million Upfront

San Diego-based Neurocrine will pay Voyager Therapeutics $165 million upfront as part of a larger pact, it was announced Jan. 29.

Illumina Reports Q4 Results

Illumina reported an 11 percent increase in fourth quarter revenue after the market closed Jan. 29.

New CEO Named at Histogen

Histogen, a regenerative medicine biotech in San Diego, has a new CEO and chairman.

La Jolla Institute for Immunology Awarded $22 Million Contract Renewal

Through a re-upped $22 million contract, the La Jolla Institute for Immunology will keep running — and expand — a database popular with researchers developing new treatments and vaccines.

San Francisco Conference Draws Complaints; Some Call for Move

Upward of $21 for a cup of coffee. Hotels as much as $2,000 a night. And $300 for a three-hour slot at a hotel lobby table.

Genetics Organizations to Merge Platforms

LunaPBC — a Solana Beach startup that in December launched a first-of-its-kind platform that gives shares for contributing DNA data — is joining forces with a like-minded nonprofit.

Tease photo

Abide Therapeutics Names New COO

Abide Therapeutics – headquartered in San Diego — has a new chief operating officer: Kevin Finney.

Tease photo

Molecular Flu Test Ready to Compete

HEALTH: Rapid Results, Simplicity Are Selling Points

A widespread desire for quicker and more accurate flu diagnostics has buoyed San Diego’s Mesa Biotech.

Tease photo

ResMed Reports Second Quarter Results

San Diego’s ResMed posted quarterly earnings of 86 cents per share, with adjusted earnings of $1 per share.

LunaPBC to Merge Platform with Genetic Alliance

LunaPBC — a Solana Beach startup that in December launched a first-of-its-kind platform that gives shares for contributing DNA data — is joining forces with a like-minded nonprofit.

Gossamer Finds a Way Around Government Shutdown for IPO

Gossamer Bio will take an alternative path to going public on account of the government shutdown stalling initial public offerings, per a Jan. 23 filing.

Tease photo

New Chief of Staff Named at Scripps Mercy Hospital

Dr. Megan Hamreus now leads a 1,100-member physician team at Scripps Mercy Hospital’s two medical campuses.

San Diego Businesses Found Lacking in Female Board Members

Under a new law, California public companies must have at least one woman on their board by the end of 2019. It appears the biggest impact will be in San Diego.

Tease photo

Mirati Shines at Healthcare Conference

At the annual J.P. Morgan Healthcare conference, major San Diego players like Illumina naturally command attention. But quietly, Mirati Therapeutics had a strong showing.

Public-Private Partnership Helps Fund Superbug Fight

Forge Therapeutics recently took in more funding — up to $11.1 million — to battle life-threatening infections called “superbugs.”

Tease photo

Retrophin Names New CEO

Earlier this month San Diego-based Retrophin’s board appointed a new president and CEO: Eric Dube.

Ligand’s Stock Falls as Analysts Debate Value

PHARMA: Co. Confident in Revenue, Cash and Portfolio

Ligand Pharmaceutical’s stock has lost more than half of its value since October, puzzling the company and most analysts, though a vocal minority are skeptical of the company’s pipeline.

Tease photo

Record Decoding of Genome May Be Big Win for Patients

MEDICINE: Rady Feat Drew on Local Biz Talent and Expertise

It was one for the record books. Researchers at Rady Children’s Institute for Genomic Medicine last February decoded a newborn’s genome in 19.5 hours.

Tease photo

Jan Caldwell Becomes Chairman of Scripps Health Board

Jan Caldwell, who has sat on Scripps Health’s board since 2012, was named board chairman, it was announced Jan. 14.

Catching Up to Care

HEALTH: San Diego at Forefront of Genomics Insurance Coverage

Ceaseless seizures took Kara Coltrin’s newborn son to the brink of death. Then came a turning point: rapid genome sequencing.

Tease photo

Cirius Therapeutics Outlines $86M IPO Plans

Liver drug developer Cirius Therapeutics on Jan. 11 put in a prospectus for an $86 million initial public offering.

State’s First Accredited Senior Emergency Department Opens in San Diego

UC San Diego Health has opened a new senior emergency department, complete with a team trained in geriatric medicine and senior-friendly architectural design.

Government Shutdown Puts Brakes on IPO Plans

The federal government shutdown has stalled San Diego biotechs knocking on the door of an initial public offering.

Salk Board Gives Interim President a Five Year Term

The Salk Institute’s board recently voted to give President Rusty Gage a five-year job extension.

Poseida Therapeutics Files for $115M IPO

Poseida Therapeutics on Jan. 4 filed for an initial public offering, seeking to raise $115 million.

ResMed Covering All the Bases With Its Acquisitions

2019 Look Ahead: Health Care

ResMed bought three companies in 2018, moves that taken together look to broaden the reach of San Diego’s largest medical device outfit this year and beyond.

Tease photo

New CEO Likely to Feel the Heat of Health Care Climate

2019 Look Ahead: Health Care

Sharp HealthCare, San Diego’s largest hospital system, will soon have a new person at the helm.

Tease photo

Gossamer Goes for Goal Of Being Biotech Force

2019 Look Ahead: Health Care

As evidenced by a planned Nasdaq listing, Gossamer Bio has grand plans.

Tease photo

Halozyme Expects Key Data On Cancer Drug

2019 Look Ahead: Health Care

San Diego’s Halozyme is headed for an inflection point. In the second half of the year, analysts expect key clinical trial data to be released on Halozyme’s pegph20 in metastatic pancreas cancer. The therapeutic candidate is in a late-stage trial, or known as phase 3.

Tease photo

Local Biotech Stocks Stumble and Fall With Market Drop

San Diego’s biotech industry took a beating as part of a larger fourth quarter stock retreat.

Tease photo

NuVasive Shakes Up Organizational Structure

San Diego medtech NuVasive cut two vice president positions and shifted the responsibilities of other management as part of a reorganization that the company announced Jan. 3.

Roswell Biotechnologies Lands $32 Million Series A Round

Roswell Biotechnologies has taken in a $32 million series A round in a bid to bring down the cost of DNA sequencing through what the company calls a molecular electronics platform.

Ligand to Pay $10 Million to Palvella In Exchange for Royalty Rights

San Diego-based Ligand Pharmaceuticals will pay $10 million to Palvella Therapeutics under a recent deal.

Equillium Definitely on Fast-Track With Drug

PHARMA: FDA Designation, Early IPO Work in Co.’s Favor

Equillium went from founding to a Nasdaq listing in only 16 months, indicating a biotech moving at warp speed.

Tease photo

Lean Strategy Makes the Most Of This Part-Time Workforce

Fortis Therapeutics wants to treat late-stage cancers with unique science — and an uncommon business model: zero full-time employees.

Tease photo

California Life Sciences Association Names New CEO

Mike Guerra will succeed Sara Radcliffe as the president and CEO of the California Life Sciences Association, the trade group announced this week.

High-Profile Role For Ionis in Local Pharma Sector

2018 Newsmakers

Every month in 2018 seemed to bring a major development at Ionis Pharmaceuticals, from a $1 billion deal to hope in Huntington’s disease.

Tease photo

Illumina Makes Statement with $1.2B Acquisition

2018 Newsmakers

Locally, billion dollar deals normally end with a San Diego firm being acquired. Tell that to Illumina.

Tease photo

Founder Departure Not Only Setback at Human Longevity

2018 Newsmakers

Once the toast of the town, Human Longevity Inc.’s valuation sunk to $310 million, down more than 80 percent from early 2017.

Tease photo

Dexcom Makes Diabetes Monitoring Breakthrough

2018 Newsmakers

Dexcom soared to new heights after the rollout of its G6 diabetes monitoring system — a small patch on the abdomen that continuously beams glucose level data to a smartphone and notifies users of dangerous glucose levels.

Tease photo

Ionis Succession Plan Puts New CEO at Helm in 2020

Ionis Pharmaceuticals, one of San Diego’s largest drugmakers, will have a new CEO in 2020.

Judge Dismisses HLI Lawsuit Accusing Venter of Trade Secret Theft

A California court on Dec. 18 dismissed a lawsuit in which Human Longevity Inc. alleged that former CEO Craig Venter took trade secrets.

Epipen Alternative to Bring Good News to Price Sensitive Users

Adamis Pharmaceuticals’ epipen alternative will launch nationally in the first quarter of next year, the company said in a recent update.

Tease photo

Medical Tourism Still Needs A Shot in the Arm

A medical tourism campaign touting San Diego’s hospitals, genomics companies and sunny weather is trying to find its groove.

Tease photo